The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $181.96

Today's change+3.09 +1.73%
Updated December 24 1:00 PM EST. Delayed by at least 15 minutes.
 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $181.96

Today's change+3.09 +1.73%
Updated December 24 1:00 PM EST. Delayed by at least 15 minutes.

Alexion Pharmaceuticals Inc up sharply

Alexion Pharmaceuticals Inc closed up sharply Wednesday, rallying (U.S.)$3.09 or 1.73% to (U.S.)$181.96. Over the last five days, shares are unchanged, but have gained 36.93% over the last year to date. This security has outperformed the S&P 500 by 25.28% during the last year.

Key company metrics

  • Open(U.S.) $179.35
  • Previous close(U.S.) $178.87
  • High(U.S.) $185.78
  • Low(U.S.) $179.34
  • Bid / Ask-- / --
  • YTD % change+36.93%
  • Volume433,756
  • Average volume (10-day)1,445,553
  • Average volume (1-month)1,165,213
  • Average volume (3-month)1,180,814
  • 52-week range(U.S.) $126.76 to (U.S.) $203.30
  • Beta0.71
  • Trailing P/E75.72×
  • P/E 1 year forward34.97×
  • Forward PEG1.14×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $2.40
Updated December 24 1:00 PM EST. Delayed by at least 15 minutes.
S&P TSX0.10%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue555512567442
Total other revenue--------
Total revenue555512567442
Gross profit503473534390
Total cost of revenue52403352
Total operating expense318294357304
Selling / general / administrative158159129135
Research & development978918883
Depreciation / amortization3333
Interest expense (income), net operating--------
Unusual expense (income)82332
Other operating expenses, total--------
Operating income237219210138
Interest income (expense), net non-operating-----1-1
Gain (loss) on sale of assets--------
Other--------
Income before tax236219212138
Income after tax178166159-19
Income tax, total585253157
Net income178166159-19
Total adjustments to net income--------
Net income before extra. items178166159-19
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items178166159-19
Inc. avail. to common incl. extra. items178166159-19
Diluted net income178166159-19
Dilution adjustment00--0
Diluted weighted average shares201202202199
Diluted EPS excluding extraordinary itemsvalue per share0.880.830.79-0.10
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share0.910.830.800.01